TSLA
Tesla
-- 421.060 PLTR
Palantir
-- 80.550 NVDA
NVIDIA
-- 134.700 OXY
Occidental Petroleum
-- 47.130 AMD
Advanced Micro Devices
-- 119.210 
NEWS
Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway
Shattuck Labs (Nasdaq: STTK) announced a strategic pipeline prioritization, discontinuing its SL-172154 clinical program due to modest improvements in overall survival for TP53 mutant AML and HR-MDS patients. The company will focus on SL-325, a first-in-class DR3 antagonist antibody for inflammatory bowel disease (IBD), with an IND filing expected in Q3 2025.
Key points:
SL-172154 showed only modest improvement in median overall survival compared to azacitidine monotherapy benchmarks
Approximately 40% workforce reduction as part of restructuring
Cash runway extended into 2027
Mutual termination of collaboration agreement with Ono Pharmaceutical
SL-325 demonstrates high affinity binding and superior efficacy over TL1A antibodies in preclinical studies
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment